Despite initial struggles, we showed some growth, prompting an investor to suggest we raise a Series A round, which I eagerly prepared for.

Despite facing a down round during our Series C funding, we continued to grow the business and raise additional capital, demonstrating resilience in a competitive market.

We raised our Series A on a prototype, which was challenging because many investors doubted our potential to become a public company.

Despite progress, raising Series A was challenging due to increased competition in the food startup space, and we faced another setback in securing funding.

By the end of 2013, we reached $500,000 in annual recurring revenue, which prompted us to start thinking about raising a Series A.

We were confident about our startup, thinking we would get a lot of PR and funding, and we did receive significant media attention and raised $1.2 million in funding.

We raised two and a half million dollars on a twelve million dollar valuation after nine months of fundraising post-Y Combinator demo day.

The hardest part of raising our Series A was overcoming the perception that we were just two academics without a viable business model.

After raising our seed round, we went on to raise about $20 million more in venture capital, taking our device through prototype stages and clinical studies, ultimately achieving FDA clearance.